Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Joe Stringer
Period: Reporting period mapped to calendar 2025 Q3.
- Questions
- 1on tracked calls
- Challenge rate
- 0%none of 1 questionLimited sample
- Companies
- 1questioned at least once
- Reporting periods
- 1with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 1 of 1 question from 1 company
GILDGilead Sciences1 question · 1 reporting period · 0 of 1 challenging
Calendar 2025 Q3
what gives you confidence that you'll get approval from FDA this time around? And two, what do you think the market opportunity for the drug is in HDV
Show response
Dietmar cited additional injection data, European real-world experience, and enhanced filing. Johanna described strategic fit with hep B footprint. HDV affects ~40,000 US patients (2% of HBV). Rare disease with accelerated cirrhosis and liver cancer risk.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| GILD Gilead Sciences | 1 | —Rate withheld: fewer than 3 questions |
- GILDGilead Sciences · 1 question—rate withheld: under 3 questions
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2025 Q3 | 1 | 0%none of 1 question | 1 |
- 2025 Q31 question · challenge rate 0% (none of 1 question) · 1 company
Topics
Topics tagged on this analyst’s questions.
- Regulation Policy1
- Product Launch1